Board of directors

Michael Wolff Jensen

Chairman

Michael Wolff Jensen is consulting CFO and Chairman of the board of Ascendis Pharma and has extensive experience in the pharmaceutical and biotechnology industry. He was a senior executive at both Genmab A/S and LifeCycle Pharma A/S directly responsible for the IPO of both companies on the OMX Nasdaq Stock Exchange (and Neuer Markt Stock Exchange for Genmab). Previous positions include Executive Vice President and Chief Financial Officer of Genmab A/S and LifeCycle Pharma A/S, lawyer for Hjejle, Gersted & Mogensen and lecturer in contractual law at the University of Copenhagen. Mr. Jensen also serves as Senior Legal Advisor for the Renewables business unit of DONG Energy.

 

Hans Arwidsson, Ph.D.

President & CEO of Eurocine Vaccines AB (publ.), is an executive with broad cross-functional experience from the pharmaceutical industry. He has extensive experience from line and project management positions in R&D, Marketing and Operations in Astra and AstraZeneca (1984-2001), where he got deep insights in all parts of the pharmaceutical product life cycle. As the CEO of LipoCore Holding AB (2001-2003), a drug delivery company in Stockholm, he developed the company´s sales and business development functions. Arwidsson is a pharmacist by training and holds a M.Sc. (1984) and a Ph.D. (1991) in pharmaceutical sciences from the University of Uppsala as well as a MBA from Stockholm School of Economics (1996).

 

Maris Hartmanis Prof.

Maris is a seasoned industrial executive and leader with almost 30 years of CEO, senior R&D management and Board of Director experience from the international Life Science area. His experience stems from large organizations, as well as entrepreneurial start-ups. Most recently he was the CEO of two Swedish public pharmaceutical companies. Maris has a Ph.D. degree in Biochemistry from the Royal Institute of Technology in Stockholm, where he also is an Associate Professor.

 

Carl-Johan Spak Ph.D.

Dr Spak is presently CEO of Recipharm Venture Fund. He graduated with a doctorate in dental surgery in 1980 and a PhD in pharmacology from the Karolinska institute in 1984. He has since held a number of positions in medical and pharma companies and currently serves as director of several technology development companies. Carl-Johan is Executive VP Development & Technology at Recipharm AB and executive director of Cobra Biologics Ltd.

 

Jan Erik Nyström Ph.D.

Associate Professor in Organic Chemistry, CEO and owner at Alveiro AB. Jan Erik Nyström is also Chairman of the Berzelius program “EXSELENT”, chairman of the Association of Surface Chemistry Research “FYF”, and board member of Institute for Surface chemistry “YKI”. He brings more than 20 years experience from various senior roles at AstraZeneca which provide a broad drug discovery background and include 10 years as medicinal chemistry director, research head, project leader, and external collaborations director in the CNS&Pain and cardiovascular research areas. He served in the AZ global project evaluation group on numerous occasions and also as chairman of the AstraZeneca R&D patent committee in Södertälje for seven years. Jan-Erik is co-author to 26 publications and 18 patent applications including an inventorship for the direct thrombin inhibitor ximelagatran (Exanta).